DDInter1101 DDInter1676
Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a transmembrane ion channel involved in the transport of chloride and sodium ions across cell membranes of the lungs, pancreas, and other organs. Mutations in the CFTR gene result in altered production, misfolding, or function of the CFTR protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to infections, lung damage, pancreatic insufficiency, and malnutrition. Lum
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Lumacaftor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enfortumab vedotin
Lumacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Meloxicam
Lumacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enasidenib
Lumacaftor {u} may lead to a major life threatening interaction when taken with {v} Tolvaptan
Lumacaftor {u} may lead to a major life threatening interaction when taken with {v} Capmatinib
Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam
Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Lumacaftor may lead to a major life threatening interaction when taken with Tolvaptan
Lumacaftor may lead to a major life threatening interaction when taken with Capmatinib